Proteon Therapeutics (PRTO) Earns Daily Media Sentiment Score of -0.04

News articles about Proteon Therapeutics (NASDAQ:PRTO) have trended somewhat negative this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Proteon Therapeutics earned a media sentiment score of -0.04 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 44.6243743936832 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Proteon Therapeutics (NASDAQ PRTO) traded up $0.10 during trading hours on Tuesday, reaching $2.50. The company had a trading volume of 241,200 shares, compared to its average volume of 100,289. The company has a market cap of $44.05, a P/E ratio of -1.13 and a beta of 1.62. Proteon Therapeutics has a one year low of $1.10 and a one year high of $2.75.

Proteon Therapeutics (NASDAQ:PRTO) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.68). sell-side analysts forecast that Proteon Therapeutics will post -1.88 EPS for the current fiscal year.

A number of brokerages have recently issued reports on PRTO. Zacks Investment Research upgraded Proteon Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 4th. Robert W. Baird restated a “hold” rating and issued a $2.00 target price on shares of Proteon Therapeutics in a research report on Friday, November 10th. Finally, HC Wainwright restated a “hold” rating and issued a $2.30 target price on shares of Proteon Therapeutics in a research report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $3.20.

In related news, Director James E. Flynn purchased 110,557 shares of the firm’s stock in a transaction on Thursday, November 30th. The shares were acquired at an average cost of $1.75 per share, with a total value of $193,474.75. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders acquired a total of 122,852 shares of company stock worth $216,533 over the last ninety days. Insiders own 36.30% of the company’s stock.

WARNING: “Proteon Therapeutics (PRTO) Earns Daily Media Sentiment Score of -0.04” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/01/16/proteon-therapeutics-prto-getting-somewhat-negative-news-coverage-report-finds.html.

About Proteon Therapeutics

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Insider Buying and Selling by Quarter for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply